BERLIN and SEATTLE, May 6, 2008 (PRIME NEWSWIRE) -- Epigenomics AG (Frankfurt:ECX) (Prime Standard), a cancer molecular diagnostics company developing tests based on DNA methylation, today reported financial results for the first quarter of 2008, which ended March 31, 2008.
